Argistad 500

Rx

Chỉ định:

• Maintenance treatment for hyperammonemia in patients with deficiency of carbamoyl phosphate synthetase, ornithine transcarbamylase.
• Maintenance treatment in patients with hyperammonemia, citrullinemia, argininosuccinic aciduria.
• Support treatment of dyspepsia.
• Support treatment to improve the exercising ability in patients with stable cardiovascular disease.
• Nutritional supplementation for patients with urea cycle disorders such as hyperammonemia type I and II, citrullinemia, argininosuccinic aciduria and with deficiency of the enzymes N-acetylglutamate synthetase.

Dosage:

• Maintenance treatment for hyperammonemia in patients with deficiency of carbamoyl phosphate synthetase, ornithine transcarbamylase in newborns and infants aged from 1–18 months: 100 mg/kg/day, divided into 3-4 times/day.
• Maintenance treatment in patients with hyperammonemia, citrullinemia, argininosuccinic aciduria in newborns and infants aged from 1–18 months: 100-175 mg/kg once, taken 3-4 times/day with food. Adjust the dosage depending on the response.
• Support treatment of dyspepsia in adults: 3-6 g/day
• Support treatment to improve the exercising ability in patients with stable cardiovascular in adults: 6-21 g/day, each dose should not exceed 8 g.
• Nutritional supplementation for patients with urea cycle disorder such as hyperammonemia type I and II, citrullinemia, argininosuccinic aciduria and with deficiency of the enzyme N-acetylglutamate synthetase in adults: 3-20 g/day depend on disease condition.

Usage:

Argistad 500 is administered orally.

Patients with known hypersensitivity to any ingredients in the formulation.

Patients with allergic tendencies.

Patients with urea cycle disorder who have arginase deficiency.

• Abdominal pain and bloating, decreased platelet count and exacerbation of acrocyanosis, exacerbation of sickle cell anemia, and elevations of BUN and serum creatine and creatinine.
• Allergic reaction, characterized by macular rash with redness and swelling of the hands and face that subsided rapidly foll.

• Arginine should be used cautiously in patients with renal disease or anuria.
• Plasma chloride and bicarbonate concentrations should be monitored and simultaneous administration of appropriate amounts of bicarbonate may be required.
• The temporary effect of a high nitrogen load on the kidneys should be evaluated before the drug is used.
• Arginine should not be used for treatment of hyperammonaemia caused by organic acidemias.
• This drug should not be used during pregnancy. Caution should be exercised when arginine is to be administered to nursing women.
• Patients should be aware of how they react to drug before driving or operating machinery.